Bibframe Work
Attrition in drug discovery and development / Scott Boyer, Clive Brealey and Andrew M. Davis
Compound attrition at the pre-clinical phase / Cornelis E.C.A. Hop
Attrition in phase I / Dennis A. Smith and Thomas A. Baillie
Compound attrition in phase II/III / Alexander Alex, C. John Harris, Wilma W. Keighley and Dennis A. Smith
Post-marketing attrition / Dennis A. Smith
Influence of the regulatory environment on attrition / Robert T. Clay
Experimental screening strategies to reduce attrition risk / Marie-Claire Peakman, Matthew Troutman, Rose Gonzales and Anne Schmidt
Medicinal chemistry strategies to prevent compound attrition / J. Richard Morphy
Influence of phenotypic and target-based screening strategies on compound attrition and project choice / Andrew Bell, Wolfgang Fecke and Christine Williams
In silico approaches to address compound attrition / Peter Gedeck, Christian Kramer, Richard Lewis
Current and future strategies for improving drug discovery efficiency / Peter Mbugua Njogu and Kelly Chibale
Impact of investment strategies, organizational structure and corporate environment on attrition, and future investment strategies to reduce attrition / Geoff Lawton
Status: changed
Date: 2020-04-16T09:59:46
Description Modifier: United States, Library of Congress
Generation Process: https://github.com/lcnetdev/marc2bibframe2/releases/tag/v2.7.0
Status: changed
Date: 2024-08-02T20:38:53.32073-04:00
Encoding Level: full
Description Level: http://id.loc.gov/ontologies/bibframe-2-3-0/
Description Conventions: ISBD: International standard bibliographic descriptionResource description and access
Identified By: bf:Local, 18727141
Description Language: English
Description Authentication: pcc